This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
coronavirus disease | 150 |
acute respiratory | 147 |
novel coronavirus | 132 |
respiratory syndrome | 124 |
severe acute | 104 |
syndrome coronavirus | 78 |
sn compr | 66 |
respiratory distress | 63 |
cancer patients | 62 |
clinical characteristics | 56 |
compr clin | 54 |
clin med | 54 |
cord uid | 53 |
med doi | 53 |
doc id | 53 |
intensive care | 53 |
cytokine storm | 52 |
remains neutral | 49 |
note springer | 49 |
springer nature | 49 |
nature remains | 49 |
published maps | 49 |
institutional affiliations | 49 |
jurisdictional claims | 49 |
risk factors | 48 |
lopinavir ritonavir | 48 |
severe covid | 48 |
distress syndrome | 47 |
clinical features | 47 |
case report | 44 |
nervous system | 41 |
authors declare | 41 |
critically ill | 39 |
systematic review | 39 |
informed consent | 37 |
respiratory tract | 37 |
hospitalized patients | 37 |
medical education | 36 |
immune system | 36 |
immune response | 35 |
patients infected | 34 |
care unit | 34 |
cohort study | 33 |
middle east | 33 |
world health | 33 |
immune thrombocytopenia | 33 |
among patients | 32 |
higher risk | 32 |
public health | 31 |
ct scan | 31 |
infected patients | 30 |
severe disease | 30 |
health organization | 30 |
increased risk | 30 |
east respiratory | 30 |
chest ct | 29 |
viral infection | 29 |
mechanical ventilation | 28 |
mortality rate | 28 |
neutralizing antibody | 27 |
emergency department | 26 |
ill patients | 26 |
coronavirus infection | 26 |
host cell | 26 |
kidney injury | 26 |
pregnant women | 26 |
case series | 26 |
incubation period | 26 |
bladder cancer | 26 |
cardiovascular disease | 26 |
spike protein | 25 |
respiratory failure | 25 |
confirmed cases | 24 |
affiliations key | 24 |
convalescent plasma | 24 |
creative commons | 24 |
blood pressure | 24 |
blood glucose | 23 |
status epilepticus | 23 |
infection control | 23 |
one patient | 22 |
polycythemia vera | 22 |
pcr test | 22 |
converting enzyme | 22 |
intravesical bcg | 22 |
nursing homes | 22 |
side effects | 22 |
diabetes mellitus | 22 |
platelet count | 22 |
ethical approval | 22 |
infectious diseases | 22 |
cerebrospinal fluid | 22 |
confirmed covid | 21 |
topical collection | 21 |
new coronavirus | 21 |
pediatric patients | 21 |
mg kg | 20 |
another study | 20 |
nucleic acid | 20 |
pulmonary fibrosis | 20 |
tested positive | 20 |
clinical course | 20 |
prone positioning | 20 |
cerebral hemorrhage | 20 |
clinical trials | 20 |
fatality rate | 20 |
viral infections | 19 |
online learning | 19 |
hubei province | 19 |
glucose levels | 19 |
patients admitted | 19 |
nursing home | 19 |
heart failure | 18 |
case reports | 18 |
commons licence | 18 |
respiratory symptoms | 18 |
clinical presentation | 18 |
intravenous immunoglobulin | 18 |
organ failure | 18 |
medical schools | 17 |
polymerase chain | 17 |
viral shedding | 17 |
icu patients | 17 |
new york | 17 |
kawasaki disease | 17 |
case fatality | 17 |
fasting glucose | 17 |
chain reaction | 17 |
coronavirus pneumonia | 17 |
ethical standards | 17 |
corona virus | 17 |
ace receptor | 17 |
elderly patients | 17 |
retrospective study | 17 |
social distancing | 16 |
immune responses | 16 |
cervical cancer | 16 |
healthcare workers | 16 |
fangcang shelter | 16 |
sars coronavirus | 16 |
antibody responses | 16 |
viral load | 16 |
march th | 16 |
viral clearance | 16 |
pediatric ed | 16 |
shelter hospital | 16 |
literature review | 16 |
central nervous | 16 |
burst suppression | 16 |
virus may | 15 |
retrospective cohort | 15 |
kidney disease | 15 |
global health | 15 |
white blood | 15 |
arima model | 15 |
inflammatory cytokines | 15 |
pseudomonas aeruginosa | 15 |
older adults | 15 |
chronic kidney | 15 |
symptom onset | 15 |
old male | 15 |
observational study | 15 |
ed visits | 15 |
upper respiratory | 15 |
older age | 14 |
home residents | 14 |
crp levels | 14 |
risk factor | 14 |
reactive protein | 14 |
patients hospitalized | 14 |
lung injury | 14 |
body temperature | 14 |
acute kidney | 14 |
respiratory system | 14 |
cardiovascular diseases | 14 |
adverse effects | 14 |
positive patients | 14 |
china clinical | 14 |
health emergency | 14 |
personal protective | 14 |
computed tomography | 14 |
patients showed | 14 |
medical conditions | 13 |
replacement therapy | 13 |
disease control | 13 |
control group | 13 |
human coronavirus | 13 |
clinical manifestations | 13 |
dysphagia management | 13 |
oxygen saturation | 13 |
general population | 13 |
hong kong | 13 |
nasopharyngeal swab | 13 |
lymphocyte count | 13 |
relevant information | 13 |
clinical outcomes | 13 |
protective equipment | 13 |
high risk | 13 |
median age | 13 |
infectious disease | 12 |
host cells | 12 |
myocardial injury | 12 |
clinical improvement | 12 |
cleavage site | 12 |
angiotensin system | 12 |
global pandemic | 12 |
close contact | 12 |
serial interval | 12 |
years old | 12 |
molecular weight | 12 |
cell surface | 12 |
respiratory disease | 12 |
significantly higher | 12 |
negative conversion | 12 |
severe cases | 12 |
british cohort | 12 |
locally advanced | 12 |
written informed | 12 |
health care | 12 |
virus infection | 12 |
control measures | 12 |
acute phase | 12 |
immune cells | 12 |
extracted relevant | 12 |
takotsubo syndrome | 12 |
york city | 12 |
disease severity | 12 |
clinical practice | 11 |
weight heparin | 11 |
venous thrombosis | 11 |
tract infections | 11 |
blood cells | 11 |
time series | 11 |
immunoglobulin replacement | 11 |
one study | 11 |
thrombocytopenic purpura | 11 |
lower respiratory | 11 |
previous studies | 11 |
odds ratio | 11 |
radiation therapy | 11 |
critical illness | 11 |
human participants | 11 |
neurological manifestations | 11 |
study clinical | 11 |
controlled trials | 11 |
vertical transmission | 11 |
chinese cohort | 11 |
doubling time | 11 |
may also | 11 |
lung disease | 11 |
evans syndrome | 11 |
neutralizing antibodies | 11 |
viral rna | 11 |
magnetic resonance | 10 |
mg day | 10 |
serum creatinine | 10 |
early stages | 10 |
false negative | 10 |
binding domain | 10 |
supplementary material | 10 |
test results | 10 |
google scholar | 10 |
one case | 10 |
atopic dermatitis | 10 |
patients without | 10 |
thorax ct | 10 |
receptor binding | 10 |
american society | 10 |
nasopharyngeal swabs | 10 |
pharmaceutical services | 10 |
pulmonary disease | 10 |
transmission dynamics | 10 |
antifibrotic therapy | 10 |
angiotensin ii | 10 |
many patients | 10 |
positive rt | 10 |
confidence interval | 10 |
patients requiring | 10 |
lymph node | 10 |
severe thrombocytopenia | 10 |
adult inpatients | 10 |
randomized controlled | 10 |
standard therapy | 10 |
coronavirus infections | 10 |
performed using | 9 |
infected pneumonia | 9 |
th day | 9 |
inflammatory markers | 9 |
will need | 9 |
dry cough | 9 |
ct showed | 9 |
impaired fasting | 9 |
northern italy | 9 |
may result | 9 |
tested negative | 9 |
density shadows | 9 |
cerebrovascular disease | 9 |
virus disease | 9 |
ischemic stroke | 9 |
brain ct | 9 |
recent study | 9 |
fake news | 9 |
new cases | 9 |
high fever | 9 |
human transmission | 9 |
cancer treatment | 9 |
air pollution | 9 |
myocardial infarction | 9 |
immunocompromised patients | 9 |
gynecological cancers | 9 |
severe illness | 9 |
covid department | 9 |
multiple organ | 9 |
endothelial cells | 9 |
negative results | 9 |
human coronaviruses | 9 |
hospital stay | 9 |
resonance imaging | 9 |
xiaogan city | 9 |
cases among | 9 |
suspected covid | 9 |
refractory status | 9 |
million people | 9 |
descriptive study | 9 |
mass media | 9 |
severe respiratory | 9 |
report date | 9 |
ckd patients | 9 |
medical records | 8 |
advanced cervical | 8 |
autoimmune etiology | 8 |
antibody response | 8 |
disease caused | 8 |
least one | 8 |
taste disorders | 8 |
kidney transplant | 8 |
patient presented | 8 |
january st | 8 |
first case | 8 |
tohid hospital | 8 |
chronic obstructive | 8 |
patient developed | 8 |
one comorbidity | 8 |
operating room | 8 |
conversion rates | 8 |
medical sciences | 8 |
underlying diseases | 8 |
tertiary care | 8 |
wuchang fangcang | 8 |
study reported | 8 |
study showed | 8 |
may st | 8 |
term care | 8 |
cognitive impairment | 8 |
clinical data | 8 |
endometrial cancer | 8 |
radiological findings | 8 |
urgent need | 8 |
significant difference | 8 |
care units | 8 |
obstructive pulmonary | 8 |
ovarian cancer | 8 |
intravesical therapy | 8 |
hospital workers | 8 |
two patients | 8 |
patients developed | 8 |
care facilities | 8 |
geriatric department | 8 |
curve fitting | 8 |
daily new | 8 |
hd patients | 8 |
retrospective studies | 8 |
two groups | 8 |
affiliations acknowledgments | 8 |
acute cerebrovascular | 8 |
inflammatory syndrome | 8 |
gastrointestinal symptoms | 8 |
monoclonal antibody | 8 |
immune thrombocytopenic | 8 |
cytokine release | 8 |
bone marrow | 8 |
chest pain | 8 |
may play | 8 |
recent studies | 8 |
left ventricular | 8 |
coronavirus outbreak | 8 |
contributed equally | 8 |
structural proteins | 8 |
therapeutic options | 8 |
sample size | 8 |
aceis arbs | 8 |
disease progression | 8 |
basal ganglia | 8 |
results showed | 8 |
external beam | 8 |
stage i | 8 |
severe patients | 8 |
underlying disease | 8 |
family cluster | 8 |
health concern | 8 |
old woman | 8 |
controlled trial | 8 |
severely ill | 8 |
medical staff | 8 |
age groups | 7 |
cancer care | 7 |
muscle strength | 7 |
robotic surgery | 7 |
open access | 7 |
reported cases | 7 |
health conditions | 7 |
ed consultations | 7 |
arima models | 7 |
hemodynamic monitoring | 7 |
necrosis factor | 7 |
prone position | 7 |
statistically significant | 7 |
cumulative confirmed | 7 |
contact history | 7 |
gynecologic cancers | 7 |
reversible encephalopathy | 7 |
infected individuals | 7 |
risk residents | 7 |
plasma exchange | 7 |
test result | 7 |
systemic review | 7 |
cardiovascular system | 7 |
hospital day | 7 |
asymptomatic patients | 7 |
mild symptoms | 7 |
serious complications | 7 |
effects model | 7 |
many medical | 7 |
important role | 7 |
tubular cells | 7 |
cardiac injury | 7 |
factors associated | 7 |
kg day | 7 |
cardiovascular comorbidities | 7 |
virus entry | 7 |
generating procedures | 7 |
comparable ethical | 7 |
common symptoms | 7 |
laboratory findings | 7 |
dimer level | 7 |
neurological symptoms | 7 |
hospital admission | 7 |
blood count | 7 |
higher prevalence | 7 |
pooled analysis | 7 |
patients died | 7 |
syndrome associated | 7 |
isolation ward | 7 |
vein thrombosis | 7 |
viral replication | 7 |
asymptomatic covid | 7 |
twice daily | 7 |
encephalopathy syndrome | 7 |
sore throat | 7 |
old age | 7 |
medical students | 7 |
blood cell | 7 |
multisystem inflammatory | 7 |
physical examination | 7 |
environmental factors | 7 |
posterior reversible | 7 |
brain tissue | 7 |
age distribution | 7 |
viral genome | 7 |
tumor necrosis | 7 |
social networks | 7 |
gastrointestinal bleeding | 7 |
day mortality | 7 |
care hospital | 7 |
gad antibody | 7 |
increased mortality | 7 |
cranial ct | 7 |
cell membrane | 7 |
humanitas gavazzeni | 7 |
laboratory tests | 7 |
saudi arabia | 7 |
large number | 7 |
smooth curve | 7 |
lung cancer | 7 |
clinical management | 7 |
patients presenting | 7 |
critical covid | 7 |
common comorbidities | 7 |
severe coronavirus | 7 |
aerosol generating | 7 |
prognostic factors | 7 |
acei arb | 7 |
deep vein | 7 |
infected patient | 7 |
transmission via | 7 |
bacillus calmette | 7 |
low molecular | 6 |
even though | 6 |
age group | 6 |
transplant patients | 6 |
adverse events | 6 |
later amendments | 6 |
international concern | 6 |
old girl | 6 |
scan imaging | 6 |
apache ii | 6 |
acute necrotizing | 6 |
several cases | 6 |
copyright holder | 6 |
high burden | 6 |
patients received | 6 |
three patients | 6 |
hepatitis virus | 6 |
permits use | 6 |
consider cytokine | 6 |
icu admission | 6 |
virus transmission | 6 |
data collection | 6 |
gustatory testing | 6 |
amino acids | 6 |
appropriate credit | 6 |
common causes | 6 |
epidemiological characteristics | 6 |
patient care | 6 |
preliminary report | 6 |
blood tests | 6 |
respiratory viruses | 6 |
third party | 6 |
supportive therapy | 6 |
heart disease | 6 |
wide range | 6 |
early stage | 6 |
renal injury | 6 |
conducted literature | 6 |
risk patients | 6 |
studies reported | 6 |
final manuscript | 6 |
diabetic patients | 6 |
intended use | 6 |
national health | 6 |
statutory regulation | 6 |
ethics committee | 6 |
european society | 6 |
hospitalised patients | 6 |
renal tubular | 6 |
cerebral venous | 6 |
ongoing pandemic | 6 |
cell entry | 6 |
first time | 6 |
node dissection | 6 |
credit line | 6 |
epithelial cells | 6 |
antiviral treatment | 6 |
ejection fraction | 6 |
short time | 6 |
conduct literature | 6 |
pcr results | 6 |
systemic inflammation | 6 |
strength training | 6 |
research center | 6 |
ace expression | 6 |
itp onset | 6 |
two studies | 6 |
per day | 6 |
intellectual content | 6 |
original author | 6 |
olfactory nerve | 6 |
moving average | 6 |
retrospective case | 6 |
remote learning | 6 |
current pandemic | 6 |
induced thrombocytopenia | 6 |
expert consensus | 6 |
respiratory infections | 6 |
standard level | 6 |
takotsubo cardiomyopathy | 6 |
party material | 6 |
mcg ml | 6 |
positively correlated | 6 |
viral entry | 6 |
significant comorbidities | 6 |
autoimmune epilepsy | 6 |
influenza virus | 6 |
normal blood | 6 |
since december | 6 |
indicated otherwise | 6 |
human controlled | 6 |
receptor blockers | 6 |
normal fasting | 6 |
traditional chinese | 6 |
spike glycoprotein | 6 |
proprotein convertases | 6 |
smoking history | 6 |
newly diagnosed | 6 |
mortality rates | 6 |
cases reported | 6 |
study concluded | 6 |
also reported | 6 |
face masks | 6 |
treatment strategies | 6 |
commons attribution | 6 |
ace protein | 6 |
five patients | 6 |
liver disease | 6 |
unless indicated | 6 |
symptomatic patients | 6 |
visit http | 6 |
give appropriate | 6 |
laboratory parameters | 6 |
gynecologic cancer | 6 |
permission directly | 6 |
pcr testing | 6 |
healthcare professionals | 6 |
infected person | 6 |
acid test | 6 |
neurological diseases | 6 |
recovered cases | 6 |
also found | 6 |
published literature | 6 |
bat origin | 6 |
transplant recipients | 6 |
fasting blood | 6 |
clinical trial | 6 |
march st | 6 |
chronic diseases | 6 |
significantly lower | 6 |
treatment guidelines | 6 |
antibiotic therapy | 6 |
treatment group | 6 |
release syndrome | 6 |
olfactory bulb | 6 |
express ace | 6 |
children needing | 6 |
obtain permission | 6 |
org licenses | 6 |
retrospective analysis | 6 |
immune dysregulation | 6 |
mild disease | 6 |
study conducted | 6 |
international license | 6 |
tissue distribution | 6 |
ace receptors | 6 |
blood oxygen | 6 |
medical educators | 6 |
immunological disorders | 6 |
mean age | 6 |
respiratory support | 6 |
infection may | 6 |
inflammatory response | 6 |
permitted use | 6 |
continuous variables | 6 |
local control | 6 |
severe bleeding | 6 |
virus neutralization | 5 |
also known | 5 |
ordinary hospitalization | 5 |
invasive ventilation | 5 |
pediatric age | 5 |
emotional stress | 5 |
specific antibodies | 5 |
clinical presentations | 5 |
chinese medicine | 5 |
aed regimen | 5 |
left parietal | 5 |
acid decarboxylase | 5 |
immunosuppressed patients | 5 |
preclinical years | 5 |
kidney failure | 5 |
will also | 5 |
close proximity | 5 |
old man | 5 |
respiratory syncytial | 5 |
resistant bacteria | 5 |
social isolation | 5 |
authorized users | 5 |
low level | 5 |
imaging showed | 5 |
transmissible gastroenteritis | 5 |
coronavirus covid | 5 |
past history | 5 |
current evidence | 5 |
condition improved | 5 |
severe critical | 5 |
higher levels | 5 |
renal function | 5 |
interstitial pneumonia | 5 |
chronic rhinosinusitis | 5 |
acute hemorrhagic | 5 |
mortality among | 5 |
target cells | 5 |
acute stage | 5 |
delayed access | 5 |
multiple sclerosis | 5 |
early diagnosis | 5 |
scoring system | 5 |
children hospitalized | 5 |
igg antibodies | 5 |
liver function | 5 |
treatment modalities | 5 |
age years | 5 |
immunodeficiency virus | 5 |
reverse transcriptase | 5 |
monitoring devices | 5 |
prospective study | 5 |
itp secondary | 5 |
electronic supplementary | 5 |
literature search | 5 |
glutamic acid | 5 |
patients clinical | 5 |
author contributions | 5 |
abdominal pain | 5 |
artificial intelligence | 5 |
male patient | 5 |
adaptive immune | 5 |
renal failure | 5 |
left ventricle | 5 |
onset itp | 5 |
intravascular coagulation | 5 |
patients referred | 5 |
many cases | 5 |
adult patients | 5 |
different countries | 5 |
breast feeding | 5 |
chronic respiratory | 5 |
rectal bleeding | 5 |
moderate symptoms | 5 |
rna viruses | 5 |
neutralization correlates | 5 |
pandemic period | 5 |
aerosol transmission | 5 |
specific antibody | 5 |
myocardial damage | 5 |
integrated moving | 5 |
preclinical phase | 5 |
system involvement | 5 |
heparan sulfate | 5 |
ill children | 5 |
central italy | 5 |
university hospital | 5 |
retrospective observational | 5 |
data show | 5 |
angiotensin receptor | 5 |
postpone brachytherapy | 5 |
propofol infusion | 5 |
asymptomatic carrier | 5 |
disease covid | 5 |
adverse reactions | 5 |
research committee | 5 |
adverse outcomes | 5 |
preclinical medical | 5 |
organ dysfunction | 5 |
pcr tests | 5 |
italian ministry | 5 |
study population | 5 |
reactive oxygen | 5 |
ras system | 5 |
recent years | 5 |
functional receptor | 5 |
older people | 5 |
syncytial virus | 5 |
ongoing covid | 5 |
gov coronavirus | 5 |
spike receptor | 5 |
developed covid | 5 |
gynecological cancer | 5 |
particulate matter | 5 |
pandemic setting | 5 |
face mask | 5 |
human tissues | 5 |
iv anesthetics | 5 |
general condition | 5 |
higher mortality | 5 |
helsinki declaration | 5 |
hazard ratio | 5 |
glass opacities | 5 |
significantly increased | 5 |
million confirmed | 5 |
human cells | 5 |
autoregressive integrated | 5 |
confirmed sars | 5 |
treatment option | 5 |
american college | 5 |
disseminated intravascular | 5 |
interquartile range | 5 |
pediatric unit | 5 |
several reports | 5 |
monoclonal antibodies | 5 |
antigen detection | 5 |
april th | 5 |
drainage tube | 5 |
storm syndromes | 5 |
intracranial infection | 5 |
cell receptor | 5 |
plasma therapy | 5 |
chest computed | 5 |
worse outcomes | 5 |
chronic lung | 5 |
ebola virus | 5 |
extremely severe | 5 |
coronavirus indicating | 5 |
glucose control | 5 |
included studies | 5 |
relative humidity | 5 |
novel corona | 5 |
pneumonia cases | 5 |
older patients | 5 |
positive sars | 5 |
hemolytic anemia | 5 |
human immunodeficiency | 5 |
brain barrier | 5 |
pulmonary function | 5 |
fibrotic tissue | 5 |
pathophysiological mechanisms | 5 |
ed access | 5 |
examination showed | 5 |
rna polymerase | 5 |
reproductive number | 5 |
pediatric emergency | 5 |
may cause | 5 |
potentially fatal | 5 |
nationwide analysis | 5 |
crystal structure | 5 |
scan showed | 5 |
early transmission | 5 |
aldosterone system | 5 |
negative rt | 5 |
predictive value | 5 |
current covid | 5 |
national research | 5 |
gastroenteritis virus | 5 |
dependent rna | 5 |
significant reduction | 5 |
case study | 5 |
randomized clinical | 5 |
expiratory muscle | 5 |
familial cluster | 5 |
negative bacteria | 5 |
antiviral drug | 5 |
united states | 5 |
online version | 5 |
acute lung | 5 |
patients treated | 5 |
care includes | 5 |
negative sars | 5 |
working group | 5 |
resistant pseudomonas | 5 |
brain infection | 5 |
baseline serum | 5 |
much higher | 5 |
early treatment | 5 |
first week | 5 |
peripheral blood | 5 |
hospital care | 5 |
human ace | 5 |
severe complications | 5 |
nasal polyp | 5 |
glass opacity | 5 |
metabolic diseases | 5 |
cytokine storms | 5 |
contains supplementary | 5 |
cases will | 5 |
risk endometrial | 5 |
preferred option | 5 |
pediatric visits | 5 |
antiviral agents | 5 |
therapeutic approaches | 5 |
studies involving | 5 |
observational cohort | 5 |
proximal tubular | 5 |
minimalist strategy | 5 |
hydroxychloroquine use | 4 |
itp patients | 4 |
ocular manifestations | 4 |
clinical symptoms | 4 |
like syndrome | 4 |
involving human | 4 |
associated acute | 4 |
febrile seizure | 4 |
author contributed | 4 |
concurrent chemoradiotherapy | 4 |
greater risk | 4 |
negative test | 4 |
gain entry | 4 |
wuhan clinical | 4 |
nosocomial covid | 4 |
elderly women | 4 |
thoracic surgery | 4 |
slightly reduced | 4 |
data regarding | 4 |
urea nitrogen | 4 |
important intellectual | 4 |
sars epidemic | 4 |
standard deviation | 4 |
show significant | 4 |
cancer treatments | 4 |
innate immune | 4 |
advanced stage | 4 |
nccn clinical | 4 |
via aerosols | 4 |
developed symptoms | 4 |
ct scans | 4 |
pathological process | 4 |
potential risk | 4 |
rapidly spread | 4 |
vascular endothelial | 4 |
previously infected | 4 |
significantly older | 4 |
hypo akinesia | 4 |
supportive care | 4 |
endoplasmic reticulum | 4 |
blocking assays | 4 |
kidney function | 4 |
critical analysis | 4 |
available data | 4 |
specific treatment | 4 |
emergency room | 4 |
samples allowing | 4 |
critically reviewed | 4 |
disease outcomes | 4 |
virus infections | 4 |
death rates | 4 |
significant effect | 4 |
negative pressure | 4 |
mental status | 4 |
care facility | 4 |
improvement compared | 4 |
chronic health | 4 |
cells accounted | 4 |
may help | 4 |
animals performed | 4 |
final version | 4 |
normal range | 4 |
positive patient | 4 |
hospitalized children | 4 |
following covid | 4 |
italian pediatric | 4 |
density lesions | 4 |
bcg may | 4 |
electronic search | 4 |
better understanding | 4 |
comorbid conditions | 4 |
logistic regression | 4 |
information regarding | 4 |
oral cavity | 4 |
dental procedures | 4 |
positive tests | 4 |
coronavirus receptor | 4 |
brain images | 4 |
may protect | 4 |
neck cancer | 4 |
hemorrhagic encephalopathy | 4 |
clinical case | 4 |
inr values | 4 |
high blood | 4 |
disease associated | 4 |
artificial neural | 4 |
two negative | 4 |
city area | 4 |
patchy high | 4 |
also shown | 4 |
beneficial effects | 4 |
mouse hepatitis | 4 |
common cold | 4 |
face teaching | 4 |
hospital staff | 4 |
studies suggest | 4 |
asymptomatic cases | 4 |
time interval | 4 |
travel history | 4 |
understanding sars | 4 |
recovered covid | 4 |
high number | 4 |
postoperative day | 4 |
often associated | 4 |
chronic renal | 4 |
may th | 4 |
underlying health | 4 |
clinical observations | 4 |
cell rna | 4 |
live virus | 4 |
positive cases | 4 |
kidney tissue | 4 |
general symptoms | 4 |
acute cardiac | 4 |
whole genome | 4 |
medical curriculum | 4 |
invasive mechanical | 4 |
might also | 4 |
mean arterial | 4 |
arterial hypertension | 4 |
first reported | 4 |
gy per | 4 |
late stage | 4 |
family members | 4 |
coronavirus nl | 4 |
oral mucosa | 4 |
lung tissue | 4 |
breath sounds | 4 |
short duration | 4 |
glasgow coma | 4 |
practice guidelines | 4 |
small molecule | 4 |
days without | 4 |
chronic disease | 4 |
high mortality | 4 |
positive result | 4 |
coronavirusinfected pneumonia | 4 |
anal swabs | 4 |
neuroinvasive potential | 4 |
neonatal care | 4 |
cardiovascular metabolic | 4 |
blood levels | 4 |
two cases | 4 |
data analysis | 4 |
ventilation support | 4 |
oxygen species | 4 |
week apart | 4 |
coronary angiography | 4 |
animal models | 4 |
human monoclonal | 4 |
stress disorder | 4 |
asymptomatic carriers | 4 |
respiratory illness | 4 |
disease prevention | 4 |
via respiratory | 4 |
pcr conversion | 4 |
hospitalized covid | 4 |
death cases | 4 |
left temporal | 4 |
patient continued | 4 |
therapeutic option | 4 |
high level | 4 |
nosocomial transmission | 4 |
adjuvant chemotherapy | 4 |
confirmed case | 4 |
covid patients | 4 |
community transmission | 4 |
cellular receptor | 4 |
prefusion conformation | 4 |
data collected | 4 |
stage ii | 4 |
pediatric visit | 4 |
urothelial carcinoma | 4 |
may represent | 4 |
chinese patients | 4 |
fatal events | 4 |
coronavirus spike | 4 |
test positive | 4 |
cervix cancer | 4 |
empirical therapeutic | 4 |
viral conjunctivitis | 4 |
treatment strategy | 4 |
crucial role | 4 |
multicenter study | 4 |
neurological disorders | 4 |
clinical suspicion | 4 |
invasive bladder | 4 |
coagulative pattern | 4 |
major public | 4 |
caesarean section | 4 |
person transmission | 4 |
adjuvant treatment | 4 |
three studies | 4 |
south korea | 4 |
stimulating factor | 4 |
false positive | 4 |
distribution curve | 4 |
retrospective tocilizumab | 4 |
negative patients | 4 |
mortality risk | 4 |
earlier virus | 4 |
ncov infection | 4 |
hospital mortality | 4 |
median blood | 4 |
allowing earlier | 4 |
coronavirus associated | 4 |
protective immunity | 4 |
may affect | 4 |
mild course | 4 |
widely used | 4 |
disease patients | 4 |
thrombotic complications | 4 |
previously healthy | 4 |
basic science | 4 |
symptoms gradually | 4 |
management guidelines | 4 |
fold higher | 4 |
protease inhibitor | 4 |
cancer surgery | 4 |
brain physiology | 4 |
getting infected | 4 |
earlier studies | 4 |
short period | 4 |
type diabetes | 4 |
gold standard | 4 |
working hours | 4 |
sars patients | 4 |
clinical research | 4 |
heart rate | 4 |
tigecycline therapy | 4 |
necrotizing hemorrhagic | 4 |
thrombotic events | 4 |
neurological recovery | 4 |
statistical analysis | 4 |
visits performed | 4 |
graph shows | 4 |
potential therapeutic | 4 |
asymptomatic infection | 4 |
bacterial infections | 4 |
patients needing | 4 |
epitope spreading | 4 |
protease tmprss | 4 |
apical ballooning | 4 |
varicella zoster | 4 |
symptoms improved | 4 |
laboratory confirmed | 4 |
complete response | 4 |
including covid | 4 |
daily pediatric | 4 |
patients suffering | 4 |
seriously affected | 4 |
salvage therapy | 4 |
respiratory diseases | 4 |
proinflammatory cytokines | 4 |
health system | 4 |
encephalitis associated | 4 |
venous thromboembolism | 4 |
associated immune | 4 |
remains unclear | 4 |
novel coronavirusinfected | 4 |
final approval | 4 |
health commission | 4 |
kidney diseases | 4 |
poor prognosis | 4 |
high rate | 4 |
clinical years | 4 |
higher education | 4 |
may lead | 4 |
clinical picture | 4 |
effects include | 4 |
like protease | 4 |
treatment trials | 4 |
temporal lobe | 4 |
hemorrhagic risk | 4 |
intracranial hemorrhage | 4 |
thrombopoietin receptor | 4 |
two countries | 4 |
pneumonia associated | 4 |
first step | 4 |
parietal region | 4 |
statistical analyses | 4 |
neurological complications | 4 |
respiratory rate | 4 |
national institute | 4 |
ii score | 4 |
severe sepsis | 4 |
symptoms like | 4 |
global covid | 4 |
better understand | 4 |
human respiratory | 4 |
acquired covid | 4 |
clinical studies | 4 |
transmembrane serine | 4 |
cerebrovascular diseases | 4 |
ventilatory support | 4 |
human trials | 4 |
first cases | 4 |
palliative radiotherapy | 4 |
clinical efficacy | 4 |
swallowing assessments | 4 |
inflammatory state | 4 |
room air | 4 |
ed visit | 4 |
cardiac performance | 4 |
underlying immune | 4 |
total number | 4 |
patients recovered | 4 |
medical staffs | 4 |
loading dose | 4 |
total patients | 4 |
arterial pressure | 4 |
adverse cardiovascular | 4 |
bleeding manifestations | 4 |
home learning | 4 |
within days | 4 |
spectrum antiviral | 4 |
major role | 4 |
clinical samples | 4 |
clinical use | 4 |
molecular mimicry | 4 |
risk group | 4 |
lessons learned | 4 |
brachytherapy unit | 4 |
without diabetes | 4 |
outcomes among | 4 |
patients dying | 4 |
high expression | 4 |
virus detection | 4 |
thromboembolic events | 4 |
wide variety | 4 |
special attention | 4 |
serious infections | 4 |
clinical response | 4 |
ncov spike | 4 |
next days | 4 |
beta coronaviruses | 4 |
higher overall | 4 |
many countries | 4 |
surgical treatment | 4 |
serine protease | 4 |
underlying medical | 4 |
smooth muscle | 4 |
clinical findings | 4 |
acute symptomatic | 4 |
viral pneumonia | 4 |
atrial fibrillation | 4 |
high levels | 4 |
virus spread | 4 |
limited data | 4 |
basic sciences | 4 |
studies show | 4 |
mostly affected | 4 |
controlled studies | 4 |
necrotizing encephalopathy | 4 |
multiple myeloma | 4 |
therapeutic plasma | 4 |
anatomy education | 4 |
severe pneumonia | 4 |
enteric nervous | 4 |
consider adjuvant | 4 |
breast cancer | 4 |
antiphospholipid antibodies | 4 |
ms patient | 4 |
significant role | 4 |
shed light | 4 |
per fraction | 4 |
respiratory droplets | 4 |
thoracic echocardiography | 4 |
blocking assay | 4 |
respiratory function | 4 |
fatality rates | 4 |
superficial bladder | 4 |
blurred state | 4 |
study published | 4 |
human interactome | 4 |
tissue damage | 4 |
eeg monitoring | 4 |
years older | 4 |
endotracheal intubation | 4 |
bcg therapy | 4 |
hospital death | 4 |
high probability | 4 |
ocular surface | 4 |
data showed | 4 |
full blood | 4 |
normal glucose | 4 |
laparoscopic surgery | 4 |
possible explanation | 4 |
cause thrombocytopenia | 4 |
authors read | 4 |
patients may | 4 |
respiratory infection | 4 |
confirmed patients | 4 |
medical treatment | 4 |
arterial duct | 4 |
infants born | 4 |
disease compared | 4 |
small group | 4 |
taste strips | 4 |
beats min | 4 |
rehabilitation process | 4 |
function tests | 4 |
high prevalence | 4 |
pathological findings | 4 |
case basis | 4 |
high sensitivity | 4 |
possible mechanisms | 4 |
clinical evolution | 4 |
admission hyperglycemia | 4 |
royal college | 4 |
pp ab | 4 |
statistical significance | 4 |
rapid spread | 4 |
em structure | 4 |
presumed asymptomatic | 4 |
chart review | 3 |
receptor recognition | 3 |
multibasic cleavage | 3 |
admission unit | 3 |
rapid review | 3 |
include gastrointestinal | 3 |
high case | 3 |
per capita | 3 |
team members | 3 |
haematological malignancies | 3 |
epidemiological data | 3 |
short doubling | 3 |
using pubmed | 3 |
asymptomatic ratio | 3 |
effectively respond | 3 |
allows us | 3 |
protease inhibitors | 3 |
genomic mrnas | 3 |
religious community | 3 |
original writing | 3 |
another patient | 3 |
effective treatment | 3 |
new deaths | 3 |
infect multiple | 3 |
retrospectively analyzed | 3 |
hiv patients | 3 |
mental health | 3 |
acute myocardial | 3 |
huanan seafood | 3 |
platelet autoantibodies | 3 |
spinal cord | 3 |
mediated cytokine | 3 |
cell types | 3 |
online teaching | 3 |
cells may | 3 |
new virus | 3 |
molecular mechanism | 3 |
internal cerebral | 3 |
digestive tract | 3 |
two modes | 3 |
united kingdom | 3 |
percentage error | 3 |
cutaneous lymphoma | 3 |
continuous infusion | 3 |
dependent enhancement | 3 |
cardiovascular complications | 3 |
worst prognosis | 3 |
one hand | 3 |
physical therapy | 3 |
important part | 3 |
coronavirus study | 3 |
global efforts | 3 |
consent informed | 3 |
plasma glucose | 3 |
multiple comorbidities | 3 |
severe conditions | 3 |
using technology | 3 |
mediated immune | 3 |
guangdong province | 3 |
septic shock | 3 |
mean absolute | 3 |
headline stress | 3 |
early detection | 3 |
improved survival | 3 |
clinical situation | 3 |
results regarding | 3 |
gynecologic malignancies | 3 |
scientific purposes | 3 |
objective testing | 3 |
family member | 3 |
minor head | 3 |
overall mortality | 3 |
cardiac tamponade | 3 |
risk disease | 3 |
get infected | 3 |
dark red | 3 |
neutralization assay | 3 |
review covid | 3 |
pulmonary fibrotic | 3 |
surgical team | 3 |
vaginal brachytherapy | 3 |
modes may | 3 |
eye protection | 3 |
phylogenetically distinct | 3 |
small case | 3 |
analysis showed | 3 |
diagnosed patients | 3 |
infusion syndrome | 3 |
unit level | 3 |
diagnostic work | 3 |
human lung | 3 |
seafood market | 3 |
respiratory coronavirus | 3 |
holidays holidays | 3 |
sars outbreak | 3 |
cancer brachytherapy | 3 |
transaminase levels | 3 |
significant increase | 3 |
partial consolidation | 3 |
mean serial | 3 |
written consent | 3 |
acquired infection | 3 |
risk cancers | 3 |
images showed | 3 |
wuhan university | 3 |
fatal cases | 3 |
may damage | 3 |
secondary demyelinating | 3 |
carboplatin paclitaxel | 3 |
new admissions | 3 |
presenting characteristics | 3 |
asymptomatic infections | 3 |
confirmed model | 3 |
sars virus | 3 |
may trigger | 3 |
one health | 3 |
research strategies | 3 |
patient showed | 3 |
stage ib | 3 |
following days | 3 |
national lockdown | 3 |
cell count | 3 |
mild covid | 3 |
john hopkins | 3 |
resistant gram | 3 |
epidemiological features | 3 |
milder course | 3 |
showed mild | 3 |
systematic analysis | 3 |
associated coronavirus | 3 |
pneumonia outbreak | 3 |
major concern | 3 |
days later | 3 |
new normal | 3 |
russian epidemic | 3 |
parental fear | 3 |
widely available | 3 |
scientific community | 3 |
radiotherapy brachytherapy | 3 |
majorly affected | 3 |
source control | 3 |
among pregnant | 3 |
tubular injury | 3 |
conditions including | 3 |
infection clinical | 3 |
acute care | 3 |
icu environment | 3 |
commonly used | 3 |
recent article | 3 |
weeks prior | 3 |
platelet production | 3 |
mixed results | 3 |
mg dl | 3 |
coronavirus rna | 3 |
home isolation | 3 |
favipiravir showed | 3 |
neutralization assays | 3 |
numerous studies | 3 |
term follow | 3 |
may need | 3 |
replicase gene | 3 |
retrospective controlled | 3 |
cumulative number | 3 |
segment hypo | 3 |
underlying etiology | 3 |
high morbidity | 3 |
procedures performed | 3 |
oncology community | 3 |
general anesthesia | 3 |
peripheral nerves | 3 |
first episode | 3 |
infection caused | 3 |
theoretical basis | 3 |
furin inhibitors | 3 |
opportunistic pathogens | 3 |
mean value | 3 |
negative rrt | 3 |
situation report | 3 |
electronic medical | 3 |
pharmacy administration | 3 |
higher likelihood | 3 |
bcg vaccination | 3 |
basal segment | 3 |
participants performed | 3 |
review articles | 3 |
body mass | 3 |
may directly | 3 |
first symptom | 3 |
negative covid | 3 |
education covid | 3 |
viral spread | 3 |
repeat infection | 3 |
renin angiotensin | 3 |
body fluids | 3 |
univariate analysis | 3 |
consultations performed | 3 |
overall case | 3 |
venous infusion | 3 |
ct brain | 3 |
complete neurological | 3 |
international society | 3 |
term prediction | 3 |
mortality due | 3 |
endometrial carcinoma | 3 |
study demonstrates | 3 |
still unclear | 3 |
animal covs | 3 |
unparalleled levels | 3 |
trial comparing | 3 |
fatal outcome | 3 |
treatment time | 3 |
kurdistan university | 3 |
secondary care | 3 |
multiple regression | 3 |
covid positive | 3 |
gastroenteritis vomiting | 3 |
vulvar cancer | 3 |
nosocomial sars | 3 |
disease infection | 3 |
normally distributed | 3 |
days prior | 3 |
meningitis encephalitis | 3 |
adverse side | 3 |
adolescents referred | 3 |
definite diagnosis | 3 |
old infant | 3 |
current knowledge | 3 |
gender difference | 3 |
respiratory viral | 3 |
online platforms | 3 |
viral particles | 3 |
precursor proteins | 3 |
healthcare staff | 3 |
june th | 3 |
hemorrhagic fever | 3 |
natriuretic peptide | 3 |
linked immunosorbent | 3 |
reported symptoms | 3 |
transplacental transmission | 3 |
hospital protocol | 3 |
may infect | 3 |
online delivery | 3 |
reverse transcription | 3 |
indicating person | 3 |
multimodal approach | 3 |
host receptor | 3 |
corticosteroid therapy | 3 |
emergency measure | 3 |
influenza viruses | 3 |
positive test | 3 |
cancer center | 3 |
health evaluation | 3 |
patients across | 3 |
rna sequencing | 3 |
convalescent sera | 3 |
several limitations | 3 |
serum levels | 3 |
ongoing clinical | 3 |
therapeutic target | 3 |
host immune | 3 |
respiratory problems | 3 |
severe course | 3 |
neoadjuvant chemotherapy | 3 |
ii endometrial | 3 |
bad prognostic | 3 |
respiratory specimens | 3 |
functional status | 3 |
sex differences | 3 |
aeruginosa infections | 3 |
storm syndrome | 3 |
genome sequencing | 3 |
northern regions | 3 |
solid tumours | 3 |
acute conjunctivitis | 3 |
highly recommended | 3 |
subsequent cases | 3 |
key medium | 3 |
patients cured | 3 |
commonly seen | 3 |
cellular protease | 3 |
showed significant | 3 |
cerebral veins | 3 |
barre syndrome | 3 |
hemorrhagic necrotizing | 3 |
pulmonary artery | 3 |
oxygen desaturation | 3 |
health threat | 3 |
effective vaccine | 3 |
existing medical | 3 |
significant risk | 3 |
daily visits | 3 |
occurred due | 3 |
american academy | 3 |
independent risk | 3 |
age decile | 3 |
including molecular | 3 |
bovine coronavirus | 3 |
clinical profile | 3 |
facilitate virus | 3 |
except one | 3 |
oropharyngeal swab | 3 |
radical hysterectomy | 3 |
one week | 3 |
dimer levels | 3 |
severe forms | 3 |
ed accesses | 3 |
initial response | 3 |
clearance rates | 3 |
crisis resolves | 3 |
induced cytokine | 3 |
catecholamine surge | 3 |
cervical carcinoma | 3 |
cardiac function | 3 |
wuhan characteristics | 3 |
rv lv | 3 |
different regions | 3 |
requiring mechanical | 3 |
onset refractory | 3 |
vaginal cancer | 3 |
radical surgery | 3 |
apparent differences | 3 |
cardiac comorbidities | 3 |
mediated epilepsy | 3 |
protective measures | 3 |
low prevalence | 3 |
subsequently discharged | 3 |
new infection | 3 |
viral loads | 3 |
regarding clinical | 3 |
search strategy | 3 |
medical practice | 3 |
infection rate | 3 |
may struggle | 3 |
gender differences | 3 |
study also | 3 |
ctd complexed | 3 |
small number | 3 |
also decreased | 3 |
high viral | 3 |
poorer prognosis | 3 |
also negative | 3 |
establish recommendations | 3 |
associated risk | 3 |
muscle cells | 3 |
rapid initiation | 3 |
potential merit | 3 |
control arm | 3 |
hospital complications | 3 |
red blood | 3 |
department visits | 3 |
geriatric rehabilitation | 3 |
plus gcsf | 3 |
data suggest | 3 |
especially furin | 3 |
potential role | 3 |
breast milk | 3 |
travel bans | 3 |
demyelinating disease | 3 |
vaccine development | 3 |
international expert | 3 |
regression model | 3 |
oral aspirin | 3 |
distancing measures | 3 |
regarding positive | 3 |
series forecasting | 3 |
indirect transmission | 3 |
renal involvement | 3 |
reports suggest | 3 |
time reverse | 3 |
cardiac arrhythmias | 3 |
swallowing assessment | 3 |
bat cov | 3 |
antiviral activity | 3 |
francesco vierucci | 3 |
acute infection | 3 |
positive pregnant | 3 |
anonymous publication | 3 |
oxygen therapy | 3 |
antigen expression | 3 |
significant benefit | 3 |
hyperglycemia without | 3 |
low priority | 3 |
white noise | 3 |
best possible | 3 |
major changes | 3 |
direct mode | 3 |
also lead | 3 |
term prognosis | 3 |
interim guidance | 3 |
needing hospitalization | 3 |
relatively new | 3 |
positive covid | 3 |
review showed | 3 |
medical professionals | 3 |
icu due | 3 |
case mix | 3 |
patients taking | 3 |
hospital setting | 3 |
gynecologic oncology | 3 |
provide source | 3 |
small sample | 3 |
retrospective multicenter | 3 |
high priority | 3 |
associated itp | 3 |
cranial nerves | 3 |
like cleavage | 3 |
blocking test | 3 |
least days | 3 |
regression equation | 3 |
cardiovascular prognosis | 3 |
will develop | 3 |
young man | 3 |
analysis prevalence | 3 |
possible role | 3 |
beam radiotherapy | 3 |
daily follow | 3 |
used alone | 3 |
may serve | 3 |
mode includes | 3 |
reported worldwide | 3 |
chemotherapy based | 3 |
pcr analysis | 3 |
transgenic animal | 3 |
significant higher | 3 |
probable bat | 3 |
wide spectrum | 3 |
confounding factors | 3 |
first recognized | 3 |
psychotic symptoms | 3 |
isolation precautions | 3 |
qt interval | 3 |
experimental treatment | 3 |
mg oral | 3 |
modified seir | 3 |
plasma ratio | 3 |
controlling covid | 3 |
cell membranes | 3 |
antibiotic treatment | 3 |
wucang fangcang | 3 |
multicenter retrospective | 3 |
soft tissue | 3 |
preventive measures | 3 |
cancer types | 3 |
authors contributed | 3 |
clinical recovery | 3 |
time polymerase | 3 |
reviewed articles | 3 |
virus particles | 3 |
clinical pictures | 3 |
every time | 3 |
interval prolongation | 3 |
epileptic drugs | 3 |
may explain | 3 |
present within | 3 |
guide future | 3 |
previous study | 3 |
cord blood | 3 |
pandemic covid | 3 |
recovery trial | 3 |
disease pneumonia | 3 |
outbreak associated | 3 |
control team | 3 |
tested covid | 3 |
borg scale | 3 |
three times | 3 |
hand hygiene | 3 |
term outcome | 3 |
disease among | 3 |
required mechanical | 3 |
medical resources | 3 |
serious implications | 3 |
molecular biology | 3 |
intravesical treatment | 3 |
million cases | 3 |
geriatric patient | 3 |
feces swabs | 3 |
significant heterogeneity | 3 |
plasma treatment | 3 |
membrane fusion | 3 |
reduced mortality | 3 |
care resources | 3 |
may predict | 3 |
true positive | 3 |
consent written | 3 |
elevated transaminase | 3 |
disease may | 3 |
median tts | 3 |
severe infections | 3 |
antigen presentation | 3 |
infectious etiology | 3 |
medical history | 3 |
underlying polycythemia | 3 |
frail older | 3 |
atypical clinical | 3 |
studies report | 3 |
bleeding complications | 3 |
vitro studies | 3 |
conceptual design | 3 |
independently significant | 3 |
second wave | 3 |
current global | 3 |
protective effect | 3 |
outside wuhan | 3 |
cell receptors | 3 |
put forward | 3 |
coronavirus outbreaks | 3 |
italian study | 3 |
without contrast | 3 |
recovered despite | 3 |
consensus recommendations | 3 |
antibody levels | 3 |
epidemiological studies | 3 |
several studies | 3 |
health organisation | 3 |
evidence suggests | 3 |
based teaching | 3 |
negative predictive | 3 |
idiopathic pulmonary | 3 |
patient died | 3 |
several countries | 3 |
postoperative icu | 3 |
cryptic antigen | 3 |
elderly people | 3 |
among covid | 3 |
online lectures | 3 |
chinese center | 3 |
management strategies | 3 |
mri features | 3 |
level ii | 3 |
pcr result | 3 |
ill covid | 3 |
hematogenic pathway | 3 |
many nursing | 3 |
median duration | 3 |
cell analysis | 3 |
patients diagnosed | 3 |
cytokines may | 3 |
third week | 3 |
key role | 3 |
antibody positivity | 3 |
also developed | 3 |
systemic inflammatory | 3 |
severe case | 3 |
higher incidence | 3 |
despite bad | 3 |
yet available | 3 |
four assessments | 3 |
cov may | 3 |
neonates born | 3 |
passive immunotherapy | 3 |
room temperature | 3 |
studies reporting | 3 |
may occur | 3 |
cardiac complications | 3 |
prospective cohort | 3 |
respiratory virus | 3 |
crisis period | 3 |
categorical variables | 3 |
significantly decreased | 3 |
underlying autoimmune | 3 |
pressure ulcer | 3 |
pentobarbital infusion | 3 |
structural basis | 3 |
fibrotic lung | 3 |
close monitoring | 3 |
systemic immune | 3 |
medical team | 3 |
illness onset | 3 |
heparin treatment | 3 |
highly contagious | 3 |
human kidney | 3 |
protect patients | 3 |
pooled odds | 3 |
induced expression | 3 |
liver cirrhosis | 3 |
discharged home | 3 |
another potential | 3 |
hyperglycemia compared | 3 |
care setting | 3 |
mild patients | 3 |
therapeutic efficacy | 3 |
carrier transmission | 3 |
mass index | 3 |
growth factors | 3 |
highly infectious | 3 |
lung cells | 3 |
nadir platelet | 3 |
fitting graph | 3 |
system capacity | 3 |
rna virus | 3 |
geriatric population | 3 |
among healthcare | 3 |
underlying cardiovascular | 3 |
clinical outcome | 3 |
stage iii | 3 |
closely monitored | 3 |
human subjects | 3 |
data available | 3 |
igm seroconversion | 3 |
strong predictor | 3 |
favipiravir shows | 3 |
lung lesions | 3 |
therapeutic strategy | 3 |
blood vessels | 3 |
disease due | 3 |
large population | 3 |
effect profile | 3 |
china reported | 3 |
positive diagnostic | 3 |
sensory neurons | 3 |
authors thank | 3 |
lymphocyte subsets | 3 |
viral surface | 3 |
risk contact | 3 |
enzyme inhibitors | 3 |
phase iii | 3 |
epidemic situation | 3 |
teaching anatomy | 3 |
entry depends | 3 |
outbreak period | 3 |
low platelet | 3 |
altered mental | 3 |
pulse rate | 3 |
sudden onset | 3 |
patient outcomes | 3 |
main cause | 3 |
many studies | 3 |
studies included | 3 |
proximal renal | 3 |
bat coronaviruses | 3 |
clinical deterioration | 3 |
brain mri | 3 |
acute admission | 3 |
may indicate | 3 |
pcs cleave | 3 |
ongoing sars | 3 |
muscle invasive | 3 |
italian population | 3 |
animal studies | 3 |
surgical staging | 3 |
preclinical curriculum | 3 |
inherent differences | 3 |
threatening condition | 3 |
infected people | 3 |
straight sinus | 3 |
platelet consumption | 3 |
po fio | 3 |
genetic predisposition | 3 |
oxidative stress | 3 |
antiviral therapy | 3 |
antiviral strategy | 3 |
molecular basis | 3 |
olfactory sensory | 3 |
care planning | 3 |
patient underwent | 3 |
patients tested | 3 |
neck surgery | 3 |
human angiotensin | 3 |
international committee | 3 |
online pedagogy | 3 |
developing severe | 3 |
head trauma | 3 |
international efforts | 3 |
lung ct | 3 |
novel virus | 3 |
motor frailty | 3 |
sars pathogenesis | 3 |
weekdays daily | 3 |
affected patients | 3 |
developed high | 3 |
didactic report | 3 |
facial twitching | 3 |
nasal congestion | 3 |
doubling times | 3 |
massive cerebral | 3 |
normal brain | 3 |
chronic liver | 3 |
main reason | 3 |
cells like | 3 |
needing ordinary | 3 |
infected cancer | 3 |
diagnostic testing | 3 |
recovery period | 3 |
left basal | 3 |
pediatric patient | 3 |
neurologic diseases | 3 |
outbreak management | 3 |
six studies | 3 |
drug therapy | 3 |
may produce | 3 |
likely related | 3 |
evidence shows | 3 |
significant gender | 3 |
patients will | 3 |
aged patients | 3 |
treatment options | 3 |
fitting effect | 3 |
blood urea | 3 |
sars cov | 3 |
oncologic emergencies | 3 |
series data | 3 |
tract symptoms | 3 |
coronavirus pandemic | 3 |
repeated twice | 3 |
weekly report | 3 |
air pollutants | 3 |
peripheral nervous | 3 |
pneumonia recovered | 3 |
exponential growth | 3 |
increasing number | 3 |
studies showing | 3 |
disease symptoms | 3 |
affiliations conflict | 3 |
chamber quantification | 3 |
pandemic situation | 3 |
credible interval | 3 |
antibacterial treatment | 3 |
neural network | 3 |
clinical marker | 3 |
highly expressed | 3 |
line agent | 3 |
liver injury | 3 |
sensory stimulation | 3 |
dysphagia assessment | 3 |
positive rate | 3 |
patients required | 3 |
studied patients | 3 |
case among | 3 |
online assessments | 3 |
neurodegenerative diseases | 3 |
wuhan city | 3 |
higher rate | 3 |
low benefit | 3 |
full ppe | 3 |
sectional study | 3 |
disease clinical | 3 |
serious adverse | 3 |
cell carcinoma | 3 |
prospective trial | 3 |
even higher | 3 |
infection spread | 3 |
severe pulmonary | 3 |
predictive values | 3 |
years may | 3 |
fatal lung | 3 |
cardiovascular damage | 3 |
dexamethasone reduced | 3 |
multicenter cohort | 3 |
disease onset | 3 |
ongoing infection | 3 |
swallowing management | 3 |
zoonotic diseases | 3 |
dysphagia assessments | 3 |
people worldwide | 3 |
rapidly evolving | 3 |
postpone treatment | 3 |
software program | 3 |
six patients | 3 |
first test | 3 |
extracellular domain | 3 |
medical community | 3 |
epidemiological parameters | 3 |
within weeks | 3 |
academic leadership | 3 |
consensus statement | 3 |
clinical status | 3 |
temporal dynamics | 3 |
prior history | 3 |
results show | 3 |
asymptomatic sars | 3 |
italy compared | 3 |
reduced number | 3 |
raised blood | 3 |
report emphasizes | 3 |
mediated autoimmune | 3 |
important lessons | 3 |
within months | 3 |
asymptomatic transmission | 3 |
laboratory results | 3 |
coronary artery | 3 |
immune mechanisms | 3 |
mg loading | 3 |
therapy schemes | 3 |
syndrome isolation | 3 |
associated pneumonia | 3 |
severe pre | 3 |
struggle later | 3 |
evaluation showed | 3 |
first draft | 3 |
elevated baseline | 3 |
prognostic indicators | 3 |
called coronavirus | 3 |
current cohort | 3 |
high proportion | 3 |
inclusion criteria | 3 |
therapeutic agents | 3 |
patent arterial | 3 |
studies showed | 3 |
droplet nuclei | 3 |
seriously ill | 3 |
rate brachytherapy | 3 |
whether covid | 3 |
advanced stages | 3 |
although many | 3 |
oncology care | 3 |
consultations requested | 3 |
like symptoms | 3 |
first trimester | 3 |
two different | 3 |
pcs family | 3 |
death among | 3 |
absolute humidity | 3 |
line drugs | 3 |
testing revealed | 3 |
deaths per | 3 |
based review | 3 |
squamous cell | 3 |
broad spectrum | 3 |
british population | 3 |
standard treatment | 3 |
healing process | 3 |
second test | 3 |
deceased patients | 3 |
showed high | 3 |
pediatric population | 3 |
also showed | 3 |
organ disease | 3 |
past days | 2 |
innovative ways | 2 |
may progress | 2 |
infection phase | 2 |
existing evidence | 2 |
interstitial lung | 2 |
protection equipment | 2 |
cases may | 2 |
showed symptoms | 2 |
diagnosing covid | 2 |
care provided | 2 |
metastatic disease | 2 |
wuhan risk | 2 |
inserting swab | 2 |
quantitative rt | 2 |
including humans | 2 |
thoracic section | 2 |
elderly patient | 2 |
also seems | 2 |
seizure activity | 2 |
included patients | 2 |
neutralization methods | 2 |
nadir count | 2 |
renal diseases | 2 |
bilateral ventricles | 2 |
stroke epidemic | 2 |
pharmacists working | 2 |
disease states | 2 |
reninangiotensin system | 2 |
change significantly | 2 |
mild thrombocytopenia | 2 |
report adverse | 2 |
fentanyl combination | 2 |
breaths min | 2 |
series study | 2 |
plex therapy | 2 |
therapeutic way | 2 |
antibody detection | 2 |
igm serology | 2 |
ab encoded | 2 |
kidney tissues | 2 |
like astrocytes | 2 |
infection evans | 2 |
treatment effect | 2 |
detailed results | 2 |
symptoms disappeared | 2 |
organ damage | 2 |
recently acquired | 2 |
iii model | 2 |
particular case | 2 |
management system | 2 |
bacille calmette | 2 |
eeg monitor | 2 |
infectious respiratory | 2 |
many aspects | 2 |
positive sera | 2 |
countries since | 2 |
analyzing patients | 2 |
adult respiratory | 2 |
patients like | 2 |
toxic shock | 2 |
balance evaluation | 2 |
highly stable | 2 |
oar pttf | 2 |
blood serum | 2 |
analysis sars | 2 |
platelet fall | 2 |
consecutive days | 2 |
antiviral intervention | 2 |
required icu | 2 |
provided critical | 2 |
abiogen pharma | 2 |
severe pandemic | 2 |
shunt meningitis | 2 |
plus paclitaxel | 2 |
time periods | 2 |
thrombocytopenia due | 2 |
eosinophil count | 2 |
combined regimen | 2 |
local immune | 2 |
surgical cases | 2 |
european country | 2 |
less susceptible | 2 |
patients aged | 2 |
viral proteins | 2 |
health professionals | 2 |
propose measures | 2 |
challenges clinical | 2 |
among hospitalized | 2 |
clinical syndrome | 2 |
analysis including | 2 |
pulmonary embolism | 2 |
systematic approach | 2 |
two categories | 2 |
recovered data | 2 |
current response | 2 |
media briefing | 2 |
initial test | 2 |
studies revealed | 2 |
clinicians must | 2 |
thorough hand | 2 |
theoretical assumptions | 2 |
daily number | 2 |
low cardiac | 2 |
substantial evidence | 2 |
deemed high | 2 |
carmen maria | 2 |
bacterial infection | 2 |
main conceptual | 2 |
alanine aminotransferase | 2 |
virus strain | 2 |
successful treatment | 2 |
health approach | 2 |
airway clearance | 2 |
brain may | 2 |
itp amid | 2 |
cells increased | 2 |
invasion mm | 2 |
case increase | 2 |
study suggests | 2 |
ultimately achieved | 2 |
major outbreak | 2 |
balance training | 2 |
collected data | 2 |
timely manner | 2 |
shedding time | 2 |
also associated | 2 |
zfcz hpd | 2 |
order truncation | 2 |
research council | 2 |
palliative chemotherapy | 2 |
kidney damage | 2 |
decreased risk | 2 |
gastrointestinal tract | 2 |
syndrome takotsubo | 2 |
omitting bvv | 2 |
external rt | 2 |
methods gave | 2 |
provide care | 2 |
academic year | 2 |
bleeding episodes | 2 |
brain homeostasis | 2 |
syndrome cardiovascular | 2 |
contradictory results | 2 |
several months | 2 |
high age | 2 |
iiib squamous | 2 |
largest rna | 2 |
ivig treatment | 2 |
multiorgan failure | 2 |
viral therapy | 2 |
patient death | 2 |
facilitating viral | 2 |
week later | 2 |
ace inhibitors | 2 |
host ace | 2 |
oxygen inhalation | 2 |
hemostatic drugs | 2 |
acute physiology | 2 |
ventilation use | 2 |
zoster virus | 2 |
significantly reduces | 2 |
study based | 2 |
complications including | 2 |
swollen left | 2 |
leading cause | 2 |
mucus plug | 2 |
poor outcomes | 2 |
returned positive | 2 |
following local | 2 |
fasting plasma | 2 |
ethics approval | 2 |
general hospital | 2 |
promising results | 2 |
chest radiographs | 2 |
median days | 2 |
compare age | 2 |
mg twice | 2 |
diagnostic ct | 2 |
plane excursion | 2 |
heparin prophylaxis | 2 |
women admitted | 2 |
including influenza | 2 |
assessment methods | 2 |
isolated sudden | 2 |
site absent | 2 |
flow cytometry | 2 |
healthy controls | 2 |
overall patients | 2 |
ill patient | 2 |
ace signal | 2 |
administered intravenously | 2 |
must consider | 2 |
severe hypoxemia | 2 |
visits also | 2 |
multiple species | 2 |
exposure prophylaxis | 2 |
clinical cases | 2 |
theoretically speculated | 2 |
structural studies | 2 |
favipiravir compared | 2 |
acid detection | 2 |
south africa | 2 |
extremely high | 2 |
fully recovered | 2 |
last century | 2 |
dose propofol | 2 |
barr virus | 2 |
spread worldwide | 2 |
observed among | 2 |
data derived | 2 |
gender impacts | 2 |
combat sars | 2 |
authors accept | 2 |
renal impairment | 2 |
brain tumor | 2 |
take note | 2 |
later stage | 2 |
zoster viruses | 2 |
article also | 2 |
minimally invasive | 2 |
health condition | 2 |
potential receptor | 2 |
rabies viruses | 2 |
sepsis caused | 2 |
bleeding versus | 2 |
princess cruise | 2 |
respiratory tracts | 2 |
per current | 2 |
delay viral | 2 |
also acts | 2 |
care community | 2 |
fairly moderate | 2 |
woman admitted | 2 |
complex concentrate | 2 |
residual sequence | 2 |
convalescent measles | 2 |
hemorrhagic conjunctivitis | 2 |
including nausea | 2 |
related infections | 2 |
ana titer | 2 |
one persistent | 2 |
significant positive | 2 |
singlestranded rna | 2 |
effective empirical | 2 |
two continents | 2 |
line therapies | 2 |
results observed | 2 |
pediatric intensive | 2 |
clinical condition | 2 |
sulfate proteoglycans | 2 |
first reports | 2 |
laboratory data | 2 |
thrombotic thrombocytopenic | 2 |
without fever | 2 |
oxygen supplementation | 2 |
th postoperative | 2 |
identified sars | 2 |
master regulator | 2 |
suspected cases | 2 |
lys arg | 2 |
doctors must | 2 |
highest percentage | 2 |
requires specific | 2 |
support staff | 2 |
serious forms | 2 |
tee probes | 2 |
sample collection | 2 |
without signs | 2 |
vam bli | 2 |
vfmzk el | 2 |
pulmonary interstitial | 2 |
approaches targeting | 2 |
igg serology | 2 |
crisis stage | 2 |
randomized study | 2 |
target cell | 2 |
temperature taking | 2 |
including patients | 2 |
day chest | 2 |
old lady | 2 |
also evident | 2 |
golgi intermediate | 2 |
pulmonary vasculature | 2 |
compassionate use | 2 |
older individuals | 2 |
curriculum using | 2 |
study involving | 2 |
maintenance therapy | 2 |
median counts | 2 |
physical activity | 2 |
mouth disease | 2 |
deepening isolation | 2 |
may present | 2 |
intensified infection | 2 |
influenza infection | 2 |
midline structure | 2 |
isolation measures | 2 |
intervention policies | 2 |
final analysis | 2 |
premorbid conditions | 2 |
since community | 2 |
science teaching | 2 |
specific keywords | 2 |
fibrosis induced | 2 |
pathogenic infections | 2 |
three hospitals | 2 |
interstitial inflammation | 2 |
mild upper | 2 |
severe degree | 2 |
recovery cases | 2 |
essential care | 2 |
control training | 2 |
di medicina | 2 |
assist breathing | 2 |
behavioral functions | 2 |
coronavirus family | 2 |
possible routes | 2 |
pelvic radiotherapy | 2 |
conduct specialized | 2 |
metastatic cervical | 2 |
mild infections | 2 |
significantly elevated | 2 |
new onset | 2 |
host lung | 2 |
hypodense areas | 2 |
learning management | 2 |
posterior leukoencephalopathy | 2 |
upper lobes | 2 |
treatment process | 2 |
peritubular capillaries | 2 |
mild hypoxemia | 2 |
org covid | 2 |
cryptic antigens | 2 |
tractus solitarius | 2 |
bergamo province | 2 |
cause meningitis | 2 |
developed due | 2 |
gene source | 2 |
assessed using | 2 |
cases date | 2 |
hydroxychloroquine sulfate | 2 |
dose volume | 2 |
infectious status | 2 |
coma scale | 2 |
diagnosed diabetes | 2 |
respiratory arrest | 2 |
dromedary camels | 2 |
clinical evaluation | 2 |
rapid test | 2 |
medium intensity | 2 |
instructed patients | 2 |
maximum effort | 2 |
subjects admitted | 2 |
cutaneous manifestations | 2 |
clinical consequences | 2 |
active covid | 2 |
antigen test | 2 |
model based | 2 |
later positive | 2 |
paraneoplastic causes | 2 |
spread sars | 2 |
tumor size | 2 |
murine hepatitis | 2 |
bulb magnetic | 2 |
care professionals | 2 |
learning environment | 2 |
intracerebral hemorrhage | 2 |
symptomatic disease | 2 |
initially reported | 2 |
adaptive learning | 2 |
pulmonary rehabilitation | 2 |
carboplatin auc | 2 |
antiviral drugs | 2 |
infusion center | 2 |
persistently positive | 2 |
average years | 2 |
commonly spread | 2 |
animal model | 2 |
bilateral salpingo | 2 |
th cytokines | 2 |
patient clinical | 2 |
risk histology | 2 |
pandemic worldwide | 2 |
active bleeding | 2 |
ultimately defined | 2 |
placental infection | 2 |
reported median | 2 |